Home › Companies › ABCELLERA BIOLOGICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ABCELLERA BIOLOGICS INC.’s Form 8-K, filed June 13, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 13, 2024: 4 items on ABCELLERA BIOLOGICS INC.’s Form 8-K, filed June 13, 2024: 2 approved · 2 passed (calculated).
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore ABCELLERA BIOLOGICS INC. in the interactive database Compare manager voting policies
These tallies are ABCELLERA BIOLOGICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Véronique Lecault, Ph.D. | 167,328,506 | 6,868,582 | 15,059,808 | -- | -- | 96% | Passed (calculated) | — |
| Elect Director: Andrew Lo, Ph.D. | 152,914,311 | 6,017,047 | 30,325,538 | -- | -- | 96% | Passed (calculated) | — |
| 2. Proposal 2 | 211,978,251 | 306,801 | 377,463 | -- | -- | 99.9% | Approved | — |
| 3. ` Proposal 3 | 176,566,724 | 7,454,852 | 5,235,320 | -- | -- | 96% | Approved | — |
Source: ABCELLERA BIOLOGICS INC., Form 8-K, filed with the SEC on June 13, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
121 asset managers disclosed a vote on at least one ABCELLERA BIOLOGICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ABCELLERA BIOLOGICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect two class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Andrew Lo
ABCELLERA BIOLOGICS INC.’s own tally for this item (“Elect Director: Andrew Lo, Ph.D.”): 152,914,311 for, 6,017,047 against, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 20 asset managers below reported 12,473,163 for, 72,000 against, 1,188,920 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Virtus | 6,133,665 | 0 | 0 | 0 | For |
| Capital Group | 4,824,565 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD FUNDS | 835,455 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 0 | 0 | 531,175 | Withhold |
| Vanguard | 480,383 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 289,836 | Withhold |
| Lazard | 0 | 0 | 0 | 147,984 | Withhold |
| OPTIMUM FUND TRUST | 119,399 | 0 | 0 | 0 | For |
| Listed Funds Trust | 0 | 0 | 0 | 107,941 | Withhold |
| American Century | 0 | 0 | 0 | 84,829 | Withhold |
| Federated Hermes | 0 | 72,000 | 0 | 0 | Against |
| State Street | 42,369 | 0 | 0 | 0 | For |
| BlackRock | 25,615 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 25,000 | Withhold |
| Fidelity | 5,360 | 0 | 0 | 0 | For |
| Brighthouse | 4,452 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 2,034 | Withhold |
| Gabelli | 1,900 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 99 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 22 | Withhold |
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect two class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Veronique Lecault
ABCELLERA BIOLOGICS INC.’s own tally for this item (“Elect Director: Véronique Lecault, Ph.D.”): 167,328,506 for, 6,868,582 against, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 20 asset managers below reported 13,691,714 for, 42,369 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Virtus | 6,133,665 | 0 | 0 | 0 | For |
| Capital Group | 4,824,565 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD FUNDS | 835,455 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 531,175 | 0 | 0 | 0 | For |
| Vanguard | 480,383 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 289,836 | 0 | 0 | 0 | For |
| Lazard | 147,984 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 119,399 | 0 | 0 | 0 | For |
| Listed Funds Trust | 107,941 | 0 | 0 | 0 | For |
| American Century | 84,829 | 0 | 0 | 0 | For |
| Federated Hermes | 72,000 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 42,369 | Withhold |
| BlackRock | 25,615 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 25,000 | 0 | 0 | 0 | For |
| Fidelity | 5,360 | 0 | 0 | 0 | For |
| Brighthouse | 4,452 | 0 | 0 | 0 | For |
| ProShares | 2,034 | 0 | 0 | 0 | For |
| Gabelli | 1,900 | 0 | 0 | 0 | For |
| Invesco | 99 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 22 | 0 | 0 | 0 | For |
Combines 13 wordings of this item as funds reported it.
85% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, or Say-on-Pay;
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Virtus | 6,133,665 | 0 | 0 | 0 | For |
| Capital Group | 0 | 4,824,565 | 0 | 0 | Against |
| BAILLIE GIFFORD FUNDS | 835,455 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 531,175 | 0 | 0 | 0 | For |
| Vanguard | 480,383 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 289,836 | 0 | 0 | 0 | For |
| Lazard | 147,984 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 119,399 | 0 | 0 | 0 | For |
| Listed Funds Trust | 107,941 | 0 | 0 | 0 | For |
| American Century | 84,829 | 0 | 0 | 0 | For |
| Federated Hermes | 72,000 | 0 | 0 | 0 | For |
| State Street | 42,369 | 0 | 0 | 0 | For |
| BlackRock | 25,615 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 25,000 | 0 | 0 | 0 | For |
| Fidelity | 5,360 | 0 | 0 | 0 | For |
| Brighthouse | 4,452 | 0 | 0 | 0 | For |
| ProShares | 2,034 | 0 | 0 | 0 | For |
| Gabelli | 0 | 1,900 | 0 | 0 | Against |
| Invesco | 99 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 22 | 0 | 0 | 0 | For |
Fund voting reports, all 20 managers: 8,907,618 for, 4,826,465 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 26,125,640 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 7,820,505 | 0 | 0 | 0 | For |
| Capital Group | 0 | 4,824,565 | 0 | 0 | Against |
| Voya | 4,490,520 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 4,180,768 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 4,105,095 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 3,873,412 | 200 | 0 | 0 | For |
| UBS | 3,633,506 | 0 | 0 | 0 | For |
| Man Group plc | 0 | 2,374,800 | 0 | 0 | Against |
| Lazard | 1,715,122 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 1,126,915 | 0 | 0 | 0 | For |
| NICOLA WEALTH MANAGEMENT LTD. | 1,013,580 | 0 | 0 | 0 | For |
| Two Sigma | 624,534 | 0 | 0 | 0 | For |
| Mediolanum International Funds Ltd | 0 | 555,383 | 0 | 0 | Against |
| BESSEMER INVESTMENT MANAGEMENT LLC | 531,175 | 0 | 0 | 0 | For |
| Baillie Gifford Investment Management (Europe) Ltd | 432,563 | 0 | 0 | 0 | For |
| DE Shaw | 343,085 | 0 | 0 | 0 | For |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 250,248 | 0 | 0 | 0 | For |
| BlackRock | 229,289 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 162,000 | 0 | 0 | 0 | For |
| Allianz | 133,078 | 0 | 0 | 0 | For |
| Polar Asset Management Partners Inc. | 117,830 | 0 | 0 | 0 | For |
| Renaissance | 95,803 | 0 | 0 | 0 | For |
| STANSBERRY ASSET MANAGEMENT, LLC | 91,533 | 0 | 0 | 0 | For |
| American Century | 84,829 | 0 | 0 | 0 | For |
Institutional-manager reports, all 103 managers: 61,920,499 for, 7,757,573 against. Showing the 25 largest; every one is in the interactive database (link above).
100% of fund votes cast · no official result
The 3 asset managers below reported 9,665,032 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TD ASSET MANAGEMENT INC | 9,658,858 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 6,174 | 0 | 0 | 0 | For |
| IPConcept (Luxemburg) S.A. | 0 | 0 | 0 | 0 | -- |
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
Description as filed by funds: To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
The 17 asset managers below reported 13,179,800 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Virtus | 6,133,665 | 0 | 0 | 0 | For |
| Capital Group | 4,824,565 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD FUNDS | 835,455 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 531,175 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 289,836 | 0 | 0 | 0 | For |
| Lazard | 147,984 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 119,399 | 0 | 0 | 0 | For |
| Listed Funds Trust | 107,941 | 0 | 0 | 0 | For |
| American Century | 84,829 | 0 | 0 | 0 | For |
| State Street | 42,369 | 0 | 0 | 0 | For |
| BlackRock | 25,615 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 25,000 | 0 | 0 | 0 | For |
| Fidelity | 5,360 | 0 | 0 | 0 | For |
| Brighthouse | 4,452 | 0 | 0 | 0 | For |
| ProShares | 2,034 | 0 | 0 | 0 | For |
| Invesco | 99 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 22 | 0 | 0 | 0 | For |
100% of fund votes cast · no official result
Description as filed by funds: To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2024.
The 3 asset managers below reported 554,283 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 480,383 | 0 | 0 | 0 | For |
| Federated Hermes | 72,000 | 0 | 0 | 0 | For |
| Gabelli | 1,900 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 294,054,356 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Virtus | 2.09% |
| 2 | Capital Group | 1.64% |
| 3 | BAILLIE GIFFORD FUNDS | 0.28% |
| 4 | OLD WESTBURY FUNDS INC | 0.18% |
| 5 | Vanguard | 0.16% |
| 6 | Columbia Threadneedle | 0.10% |
| 7 | Lazard | 0.05% |
| 8 | OPTIMUM FUND TRUST | 0.04% |
| 9 | Listed Funds Trust | 0.04% |
| 10 | American Century | 0.03% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 8.88% |
| 2 | BAILLIE GIFFORD & CO LTD | 2.66% |
| 3 | Capital Group | 1.64% |
| 4 | Voya | 1.53% |
| 5 | ORBIMED ADVISORS LLC | 1.42% |
| 6 | ArrowMark Colorado Holdings LLC | 1.40% |
| 7 | BAILLIE GIFFORD OVERSEAS LTD | 1.32% |
| 8 | UBS | 1.24% |
| 9 | Man Group plc | 0.81% |
| 10 | Lazard | 0.58% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Carl L.G. Hansen | 60,740,524 | 20.66% | Schedule 13G, filed February 13, 2024 |
| Thermopylae Holdings Ltd. | 55,802,493 | 18.98% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Baillie Gifford & Co | 24,044,796 | 8.18% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Baker Bros. Advisors LP | 22,909,753 | 7.79% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Véronique Lecault, Ph.D. | 11,910,899 | 4.05% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Andrew Booth | 5,570,249 | 1.89% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| BlackRock | 3,641,779 | 1.24% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 2,792,142 | 0.95% | Form 13F, quarter ended March 31, 2024 |
| Tryn Stimart | 2,121,642 | 0.72% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Michael Hayden, MBCHB (M.D.), Ph.D. | 1,891,456 | 0.64% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
Percentages above are of 294,054,356 shares outstanding, as reported by ABCELLERA BIOLOGICS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ABCELLERA BIOLOGICS INC.'s shareholder meeting held June 13, 2024, in the 2023-2024 proxy season, 121 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 248 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ABCELLERA BIOLOGICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — the reporting funds and managers cast 85% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ABCELLERA BIOLOGICS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ABCELLERA BIOLOGICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “ABCELLERA BIOLOGICS (ABCL) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/abcellera-biologics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.